Substantiating clinical outcomes and physician credentials in marketing

The FTC's own guidance is the clearest free primer: FTC Health Products Compliance Guidance.

Building the evidence file for a survival claim

Take "94% cancer survival rate." Here is what the file must contain before launch.

1. The exact metric definition

"Survival rate" is ambiguous. You must specify:

• 5-year relative survival (the standard oncology measure): the percentage of patients alive five years after diagnosis, adjusted for deaths unrelated to the cancer.
• The cancer type and stage. A 94% figure is plausible for localized breast or prostate cancer but not for late-stage pancreatic cancer. A blended "cancer" number across all types is meaningless and likely deceptive.

2. The source and the denominator

Where did the number come from? Options:

• Your own patient registry (then: how many patients? 30 cases is not a rate).
• A national benchmark like the US SEER program (Surveillance, Epidemiology, and End Results), run by the National Cancer Institute.

A claim built on 28 patients over two years is statistically thin. If your denominator is small, the claim is fragile.

3. The worked calculation

Say your file shows: 500 patients diagnosed with localized prostate cancer, 470 alive at five years (adjusted for unrelated deaths).

Now the honesty test: is 94% *better than average*? US SEER data has long shown localized prostate cancer 5-year relative survival near 99% (NCI estimate, check the current SEER release for the as-of date). If the national figure is higher than yours, advertising "94%" as a mark of excellence is misleading by implication. The number is technically true but creates a false impressionimpressionThe total number of times an ad or piece of content is displayed, regardless of clicks. Each display counts as one impression, even to the same person.View full definition →, and the FTC treats implied claims exactly like express ones.

4. The comparison claim trap

"Better survival than the national average" is a comparative claim. It requires a valid, apples-to-apples comparison: same cancer, same stage, same measure, same time window, and a cited source. Comparing your localized-only cohort to a national all-stages average is the classic deception. Regulators call this cherry-picking the denominator.

5. The disclaimer

Disclaimers must be clear and conspicuous (FTC language: prominent, not buried in fine print). On a billboard, a disclaimer nobody can read at 65 mph does not cure a misleading headline. The FTC rule: a disclaimer cannot fix a claim that is deceptive on its face. It can only clarify a claim that is truthful but needs context (for example, "5-year relative survival, localized prostate cancer, [source], [year]").

🎬 [VIDEO: "Truth In Advertising: The Basics" - youtube.com - FTC-style overview of substantiation and the clear-and-conspicuous disclaimer standard]

Substantiating physician credentials

The second common claim: "Our surgeons are board-certified experts." Credential claims have their own evidence file.

Board certification is verifiable, so verify it

"Board-certified" is not marketing language. It is a defined status. In the US, verify through the ABMS (American Board of Medical Specialties) certification database before you publish. Your file needs a dated screenshot or record showing each named physician is *currently* certified in the specialty you are advertising.

Common errors that become deceptive claims:

• Advertising a physician as "board-certified in oncology" when they are certified in internal medicine and only *practice* oncology.
• Continuing to run an ad after a physician's certification has lapsed or they have left the hospital.
• Using "expert" or "leading" as if they were credentials. These are puffery (subjective boasts) up to a point, but paired with specifics ("leading, with a 94% success rate") they become objective claims that need proof.

"Top doctor" and award logos

If the ad uses a "Top Doctors" badge or a US News ranking, the file must hold the license or permission to use that mark and the methodology behind it. State medical boards restrict how physicians describe their qualifications. Misrepresenting specialty status can trigger board discipline separate from any FTC action.

Testimonials and patient stories

A patient saying "this surgeon saved my life" is a testimonial, and under FTC rules a testimonial implies typical results. If the patient's outcome is unusual, you need a disclaimer stating results are not typical, or better, data showing what typical looks like. The FTC updated its endorsement guides in 2023 to tighten exactly this area, including fake or incentivized reviews. Do not run a testimonial you cannot back.

The pre-launch compliance check

Before any quality or credential claim runs, route it through a fixed checklist. Treat this as the gate between the creative team and the media buy.

Marketing compliance checklist

1. Claim inventory. List every objective claim in the asset, including *implied* ones ("best cancer care" implies a comparison).

2. Substantiation link. For each claim, attach the specific document, dataset, or certification record. No document, no claim.

3. Denominator and date check. Confirm sample size, cancer type, stage, measure, and the as-of date of the data. Stale data (a survival figure from a cohort that predates a treatment change) is a red flag.

4. Comparison validity. If comparative, confirm the benchmark is apples-to-apples and sourced.

5. Disclaimer placement. Confirm the disclaimer is clear and conspicuous in the actual format (billboard, 15-second radio spot, social post). Format matters: a disclaimer that works on a webpage may vanish on Instagram.

6. Credential currency. Re-verify board certification and employment status within a set window before launch, and set an expiry to re-check.

7. Fair-treatment review. Does the ad target or exclude a group unfairly, or exploit fear ("act now or the cancer wins")? Fear-based health advertising draws scrutiny under both FTC deception rules and state UDAP laws.

8. Sign-off log. Record who approved, when, and against which version. When a regulator asks "what did you hold before you ran this," the log is your answer.

Why the file matters more than the claim

The legal test is not "was the claim true." It is "did you have a reasonable basis at the time you made it." A survival rate that turns out accurate but had no supporting file when it ran is still an unsubstantiated claim. The file, held *before* launch, is the compliance product. The billboard is just its public face.

Key takeaways

• Substantiate before you publish. The FTC standard is a reasonable basis held *before* the claim runs, not proof gathered after a complaint.
• Define the metric precisely. "94% survival" means nothing without cancer type, stage, the 5-year relative-survival definition, sample size, source, and date.
• Comparisons must be apples-to-apples. Cherry-picking a favorable denominator (localized-only vs national all-stages) is the most common deceptive quality claim.
• Credentials are verifiable facts, not adjectives. Confirm current ABMS board certification, name the exact specialty, and re-check before every campaign.
• The checklist is the deliverable. A claim inventory, substantiation links, disclaimer placement, and a dated sign-off log are what protect the hospital when a regulator asks what you held.

*This lesson is educational and not legal or medical advice. Confirm current SEER, ABMS, FTC, and EU/ASA rules against their official sources for your launch date.*